BMY
Bristol-Myers Squibb Company
62.90$
+2.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -33.1% | +45.3% | +72.5% | +34.0% | +14.2% | +74.2% | +15.3% | -19.4% | +6.1% | +9.6% | -6.8% | |
| – | -19.5% | +1.6% | +106.5% | -19.3% | +174.1% | +494.5% | +2.9% | -3.8% | -5.0% | -1.6% | -58.2% | |
| – | +10.3% | -12.8% | -2.9% | +11.1% | +99.5% | +76.6% | -25.2% | -21.6% | +13.3% | -2.1% | +9.1% | |
| – | – | -89.3% | +2,412.3% | -44.8% | -106.9% | – | – | – | – | – | – | |
| – | -403.7% | – | – | -89.9% | +1,312.4% | -67.9% | -227.5% | – | – | – | -156.2% | |
| – | +55.9% | +48.2% | -13.2% | -9.9% | -12.1% | -9.9% | +29.2% | +14.9% | +8.1% | +3.2% | +5.0% | |
| – | -229.3% | – | -104.5% | +2,930.3% | +388.5% | +11.1% | -95.0% | +97.4% | +116.1% | +830.4% | -80.6% | |
| – | +3.3% | +2.8% | +1.2% | +1.4% | +2.5% | +52.1% | +7.9% | +5.4% | +2.4% | +2.5% | +3.7% | |
| – | +235.7% | -128.2% | +968.8% | -87.0% | +2,181.3% | -78.8% | +306.7% | +27.3% | -35.6% | -100.0% | – | |
| – | +248.0% | – | +800.9% | -155.3% | – | -77.7% | -257.4% | -14.1% | – | +2,114.0% | -151.3% | |
| – | +48.7% | -26.8% | +53.7% | -13.3% | – | -115.1% | +1,309.6% | +4.5% | -44.5% | – | -301.8% | |
| – | -260.5% | – | -36.1% | +25.8% | +296.6% | -63.6% | -130.5% | – | – | -153.4% | – | |
| – | -51.0% | +43.4% | +129.0% | +44.9% | +18.3% | +83.9% | +14.5% | -21.6% | +5.9% | +10.2% | -7.9% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.